JP2022522404A5 - - Google Patents

Info

Publication number
JP2022522404A5
JP2022522404A5 JP2021543384A JP2021543384A JP2022522404A5 JP 2022522404 A5 JP2022522404 A5 JP 2022522404A5 JP 2021543384 A JP2021543384 A JP 2021543384A JP 2021543384 A JP2021543384 A JP 2021543384A JP 2022522404 A5 JP2022522404 A5 JP 2022522404A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
acid sequence
mhc class
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522404A (ja
JP7691927B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019244 external-priority patent/WO2020180501A1/en
Publication of JP2022522404A publication Critical patent/JP2022522404A/ja
Publication of JP2022522404A5 publication Critical patent/JP2022522404A5/ja
Application granted granted Critical
Publication of JP7691927B2 publication Critical patent/JP7691927B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543384A 2019-03-06 2020-02-21 Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 Active JP7691927B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814715P 2019-03-06 2019-03-06
US62/814,715 2019-03-06
PCT/US2020/019244 WO2020180501A1 (en) 2019-03-06 2020-02-21 T-cell modulatory antigen-presenting polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022522404A JP2022522404A (ja) 2022-04-19
JP2022522404A5 true JP2022522404A5 (https=) 2023-03-01
JP7691927B2 JP7691927B2 (ja) 2025-06-12

Family

ID=72338064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543384A Active JP7691927B2 (ja) 2019-03-06 2020-02-21 Ｔ細胞調節抗原提示ポリペプチド及びその使用方法

Country Status (4)

Country Link
US (1) US20220106378A1 (https=)
EP (1) EP3935079A4 (https=)
JP (1) JP7691927B2 (https=)
WO (1) WO2020180501A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
LT3615674T (lt) 2017-04-28 2024-09-25 The Regents Of The University Of Colorado, A Body Corporate Reumatoidinio artrito gydymo būdai, naudojant nukreipiančios rnr hla geno redagavimą genome
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
AU2022263441A1 (en) * 2021-04-21 2023-11-09 Cue Biopharma, Inc. Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
WO2022226073A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides and methods of use thereof
AU2022261908A1 (en) * 2021-04-21 2023-10-05 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
KR20240023035A (ko) 2021-05-10 2024-02-20 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 자가면역 치료를 위한 hla 조작 방법 및 조성물
WO2022251552A2 (en) * 2021-05-26 2022-12-01 Cue Biopharma, Inc. Antigen presenting polypeptide complexes and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1996004314A1 (en) * 1994-07-29 1996-02-15 Dade International, Inc. Mhc complexes and uses thereof
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
EP1578917A4 (en) 2001-07-19 2008-01-23 Perlan Therapeutics Inc MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
AU2007223855B2 (en) 2006-03-06 2013-05-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US9695410B2 (en) * 2010-07-15 2017-07-04 Technion Research & Development Foundation Limited Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides
US10816554B2 (en) * 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
AU2015249592A1 (en) 2014-04-24 2016-12-15 Immusant, Inc. Use of Interleukin-2 for diagnosis of Celiac disease
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
DK3215528T3 (da) * 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
EP3291832B1 (en) * 2015-05-06 2025-09-03 UTI Limited Partnership Nanoparticle compositions for sustained therapy
CA3014466A1 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN109689096A (zh) * 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
US20180127481A1 (en) * 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES
EP3678677A4 (en) * 2017-09-07 2021-06-16 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
WO2022056014A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022522404A5 (https=)
JP2021500855A5 (https=)
Todd et al. A molecular basis for genetic susceptibility to insulin-dependent diabetes mellitus
Bonneville et al. Intestinal intraepithelial lymphocytes are a distinct set of γδ T cells
Reiner et al. TH1 and TH2 cell antigen receptors in experimental leishmaniasis
Born et al. Recognition of a peptide antigen by heat shock--reactive γδ T lymphocytes
Matis et al. Structure and specificity of a class II MHC alloreactive γδ T cell receptor heterodimer
JP5802661B2 (ja) α１−α３単量体を含むＨＬＡ−Ｇの多量体ポリペプチド及び医薬としてのその使用
TWI311564B (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
Steinman The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease
JP2023541366A5 (https=)
WO2021211455A1 (en) Hla class i-restricted t cell receptors against lmp2
JP2018506287A5 (https=)
Tabata et al. Characterization of self-glutamic acid decarboxylase 65-reactive CD4+ T-cell clones established from Japanese patients with insulin-dependent diabetes mellitus
JP2023527613A (ja) Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
Miller et al. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases
JP2022523024A5 (https=)
CN106459175A (zh) 结合至源自人前胰岛素原(ppi)蛋白的alwgpdpaaa的t细胞受体
Antonsson et al. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR
CN109562171B (zh) MHC Ia类开放型构象异构体
EP0286447B1 (en) Method and agents relating to prophylactic treatment of autoimmune diseases
Abromson-Leeman et al. T cell responses to myelin basic protein in experimental autoimmune encephalomyelitis-resistant BALB/c mice
CN100364611C (zh) 肽基免疫治疗剂
WO2022026358A1 (en) Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination
Brett et al. Antigen presentation to specific T cells by la molecules selectively altered by site-directed mutagenesis